Stoke Therapeutics, Inc. (STOK)
| Market Cap | 1.98B |
| Revenue (ttm) | 184.42M |
| Net Income (ttm) | -6.89M |
| Shares Out | 59.15M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 401,794 |
| Open | 33.89 |
| Previous Close | 33.71 |
| Day's Range | 33.25 - 33.89 |
| 52-Week Range | 8.30 - 40.22 |
| Beta | 1.22 |
| Analysts | Strong Buy |
| Price Target | 39.20 (+17.12%) |
| Earnings Date | May 8, 2026 |
About STOK
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i... [Read more]
Financial Performance
In 2025, Stoke Therapeutics's revenue was $184.42 million, an increase of 404.50% compared to the previous year's $36.56 million. Losses were -$6.89 million, -92.26% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for STOK stock is "Strong Buy." The 12-month stock price target is $39.2, which is an increase of 17.12% from the latest price.
News
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Zorevunersen demonstrates robust, durable seizure reduction and cognitive improvements in Dravet syndrome, with strong long-term safety and efficacy data. Regulatory focus is on phase III completion by Q2 2026, aiming for approval in late 2027. Longitudinal data and broad addressable market underpin commercial strategy.
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Stoke Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The EMPEROR phase III study for Dravet syndrome is on track, with robust long-term data supporting both seizure reduction and cognitive improvement. Market access and pricing strategies are aligned with other disease-modifying therapies, and manufacturing preparations are advancing for regulatory filings.
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Durable seizure reduction and neurodevelopmental improvements in Dravet syndrome are supported by four-year data, with a pivotal phase 3 readout expected in mid-2027. The company is expanding into ADOA and maintains a strong cash runway into 2028.
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today ...
Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Anchor Line Partners Supports Stoke Therapeutics' Growth by Securing a 98,500 Square-Foot Lease in Waltham, MA
New Headquarters Will Support Company's Work to Deliver zorevunersen, a Potential Disease-Modifying Medicine, to Patients with Dravet Syndrome and Expansion of Research Efforts Lease is One of the Lar...
Stoke Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company is advancing zorevunersen for Dravet syndrome, with Phase III enrollment expected to complete in Q2 2026 and potential approval as early as Q4 2027. Four-year data show durable seizure reduction and neurocognitive benefits, while a strong pipeline and financial position support future growth.
Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
BEDFORD, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with R...
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
Stoke Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Leadership transition solidifies strategic focus on genetic diseases, with lead therapy for Dravet syndrome showing durable seizure reduction and cognitive benefits. Phase III is progressing well, with full enrollment expected by H2 2026 and data in H2 2027. Financial position is strong, supporting pipeline and commercial plans.
Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Earnings Call Transcript: Q3 2025
Zorevunersen advanced in phase III for Dravet Syndrome, with robust long-term efficacy and safety data supporting potential expedited FDA review. Financials remain strong with $328.6M in cash and a cash runway into mid-2028, while pipeline programs in ADOA and SYNGAP1 progress as planned.
Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and h...
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicines, today...
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
Stoke Therapeutics Appoints Ian F. Smith as Chief Executive Officer
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today ...